News

[headingblock headingblock_text="FUS-ALS is a rare genetic form of ALS caused by variants in the FUS gene, accounting for less than one per cent of all ALS cases. FUS-ALS can be more common among people who develop ALS at a young…

Community-driven fundraiser challenges participants to pull a 42,000-lb transport truck in support of people affected by ALS, making it easier than ever for individuals and teams to get involved TORONTO, September 16, 2026 – This fall, the ALS Society…

Award continues Kevin’s legacy of helping young people affected by ALS pursue their educational and career aspirations TORONTO, September 9, 2026 – The ALS Society of Canada (ALS Canada), together with the family and friends of Kevin Daly through…

Our bimonthly Clinical Research & Trials Update keeps you up to date on what’s happening in ALS clinical research. We unpack trial press releases, flag upcoming studies, and highlight important new publications, including care guidelines, long-term therapy data, and off-label treatment insights.  For other news on…

* Neurofilament light (NfL) is a protein released when neurons are damaged and can be detected in the cerebrospinal fluid and blood. In ALS, higher NfL levels are generally associated with more rapid disease progression, at a group level. In clinical…

Our bimonthly Fundamental Research Update keeps you informed about the latest advances in lab-based ALS research. We break down new studies using cellular and animal models, highlight progress on promising preclinical targets, breakdown trending research news, and showcase Canadian led science.  For other news on clinical research and trials, read our Clinical Research & Trials Updates.  ALS…

This blog series is a place for the ALS community to learn about and stay updated on ALS Canada's advocacy efforts as well as relevant developments within the government. Please note that because ALS Canada…

PrimeC, an investigational therapy by NeuroSense Therapeutics, combines two existing prescription drugs: the antibiotic ciprofloxacin and the anti‑inflammatory drug celecoxib. Together, they are thought to target three biological processes linked to ALS: inflammation in the brain, abnormal microRNA activity (small RNA molecules that help regulate…